Obesity Overview

Obesity is recognized as a chronic or non-communicable disease, a complex, multifactorial phenotype, affecting, along with overweight, primarily associated with excess adiposity or body fatness which can manifest metabolically and not just concerning the size of the body.

“Obesity Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Obesity Market.

The Obesity Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Obesity Pipeline Report:

• Companies across the globe are diligently working toward developing novel Obesity treatment therapies with a considerable amount of success over the years. Obesity Key players such as – D&D Pharmatech, Caliway Biopharmaceutics, Nano Precision Medical, Bukwang Pharmaceutical, Yuhan, Tonix Pharmaceuticals, BioRestorative Therapies, SCOHIA PHARMA, Click Therapeutics, Hanmi Pharmaceuticals, Novo Nordisk, Sciwind Biosciences, Empros Pharma, Carmot Therapeutics, Eli Lilly and Company, Oral Novo Nordisk, and others, are developing therapies for the Obesity treatment 

• Obesity Emerging therapies such as – DD03, CBW-520, NPM 139, BK-1701, YH34160, TNX-2900, Thermostem, SCO-267, CT-181, HM15136, NNC0480-0389, XW003, EMP-16, CT-868, Tirzepatide, Semaglutide, and others are expected to have a significant impact on the Obesity market in the coming years.  
• In February 2022, Carmot Therapeutics initiated a randomized, double-blind, placebo-controlled, parallel-group,multiple-center study to evaluate the efficacy, safety, and tolerability of CT-868 administered for 26 weeks to overweight and obese participants with Type 2 diabetes mellitus 
• In October 2022, Eli Lilly and Company announced that the US Food and Drug Administration (FDA) has granted FastTrack Designation (FTD) for the investigation of tirzepatide for the treatment of adults with obesity or overweight with weight-related comorbidities
• In April 2021, Eli Lilly and Company initiated a randomized, double-blind, placebo-controlled, Phase III study comparing the efficacy and safety of Tirzepatide vs. placebo in patients with heart failure with preserved ejection fraction and obesity (SUMMIT)
• In May 2021, Carmot Therapeutics US FDA cleared an IND application for CT-868, Carmot’s dual GLP-1, and GIP receptor modulator
• In May 2021, Eli Lilly and Company initiated a randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of once-weekly Tirzepatide in participants with obesity disease. The trial is currently active with 261 participants and is anticipated to be complete by June 2023

Route of Administration

Obesity pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Molecule Type

Products have been categorized under various Molecule types, such as

• Monoclonal Antibody
• Peptides 
• Polymer 
• Small molecule
• Gene therapy

Obesity Pipeline Therapeutics Assessment

• Obesity Assessment by Product Type
• Obesity By Stage and Product Type
• Obesity Assessment by Route of Administration
• Obesity By Stage and Route of Administration
• Obesity Assessment by Molecule Type
• Obesity by Stage and Molecule Type

DelveInsight’s Obesity Report covers around products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Some of the key companies in the Obesity Therapeutics Market include:

Key companies developing therapies for Obesity are – ERX Pharmaceuticals, Amgen, Allysta Pharmaceuticals, Empros Pharma, Innovent Biologics, Pfizer, Boehringer Ingelheim, MedImmune LLC, Scohia Pharma, Eli Lilly and Company, and others.

Emerging Obesity Drugs Under Different Phases of Clinical Development Include:

• DD03: D&D Pharmatech
• Semaglutide oral: Novo Nordisk
• CBW-520 Caliway Biopharmaceutics
• NPM 139 Nano Precision Medical
• Tirzepatide: Eli Lilly and Company
• BK-1701 Bukwang Pharmaceutical
• YH34160 Yuhan
• Tesomet: Saniona
• TNX-2900 Tonix Pharmaceuticals
• RZL-012: Raziel Therapeutics
• Thermostem BioRestorative Therapies
• DD01: D&D Pharmatech
• CT-868: Carmot Therapeutics
• SCO-267 SCOHIA PHARMA
• EMP16: Empros Pharma
• CT-181 Click Therapeutics   
• ZP 8396: Zealand Pharma    
• HM15136 Hanmi Pharmaceuticals
• NNC0480-0389 Novo Nordisk
• ERX-1000: ERX Pharmaceuticals
• XW003 Sciwind Biosciences
• EMP-16 Empros Pharma
• CT-868 Carmot Therapeutics
• Tirzepatide Eli Lilly and Company
• Semaglutide Oral Novo Nordisk

Get a Free Sample PDF Report to know more about Obesity Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/obesity-pipeline-insight

Obesity Pipeline Analysis:

The Obesity pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Obesity with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Obesity Treatment.
• Obesity key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Obesity Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Obesity market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Obesity product details are provided in the report. Download the Obesity pipeline report to learn more about the emerging Obesity therapies

Obesity Pipeline Market Drivers

• Rise in prevalence of Obesity
• Growing Research and Development Activities to develop novel therapies to treat obesity
• Changing lifestyle patterns

Obesity Pipeline Market Barriers

• Challenges associated with the discovery of anti-obesity drugs
• Economic burden associated with obesity

Scope of Obesity Pipeline Drug Insight    

• Coverage: Global
• Key Obesity Companies: , and others
• Key Obesity Therapies: DD03, CBW-520, NPM 139, BK-1701, YH34160, TNX-2900, Thermostem, SCO-267, CT-181, HM15136, NNC0480-0389, XW003, EMP-16, CT-868, Tirzepatide, Semaglutide, and others
• Obesity Therapeutic Assessment: Obesity current marketed and Obesity emerging therapies
• Obesity Market Dynamics: Obesity market drivers and Obesity market barriers 

Request for Sample PDF Report for Obesity Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report to know more about Obesity drugs and therapies

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting